Cargando…
Antifibrinolytics use during surgery for oncological spine diseases: A systematic review
BACKGROUND: Data exist of the benefits of antifibrinolytics such as tranexamic acid (TXA) in general spine surgery. However, there are limited data of its use in oncological spine patients. METHODS: A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805626/ https://www.ncbi.nlm.nih.gov/pubmed/36600747 http://dx.doi.org/10.25259/SNI_837_2022 |
_version_ | 1784862369052098560 |
---|---|
author | Avila, Mauricio J. Orenday-Barraza, José Manuel Cavagnaro, María José Strouse, Isabel M. Farhadi, Dara S. Khan, Naushaba Hussein, Amna Baaj, Ali A. |
author_facet | Avila, Mauricio J. Orenday-Barraza, José Manuel Cavagnaro, María José Strouse, Isabel M. Farhadi, Dara S. Khan, Naushaba Hussein, Amna Baaj, Ali A. |
author_sort | Avila, Mauricio J. |
collection | PubMed |
description | BACKGROUND: Data exist of the benefits of antifibrinolytics such as tranexamic acid (TXA) in general spine surgery. However, there are limited data of its use in oncological spine patients. METHODS: A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Cochrane, OVID, and Embase databases were searched. Search terms: “tranexamic acid”, “aprotinin,” “aminocaproic acid,” “spine surgery,” “spine tumors,” and “spine oncology.” Included studies were full text publications written in English with patients treated with either agent or who had surgery for oncological spine disease (OSD). RESULTS: Seven hundred results were reviewed form the different databases, seven were selected. A total of 408 patients underwent spine surgery for OSD and received antifibrinolytics. There was a male predominance (55.2%) and mean age ranged from 43 to 62 years. The most common tumor operated was metastatic renal cancer, followed by breast and lung. Most studies administered TXA as a bolus followed by an infusion during surgery. Median blood loss was of 667 mL (253.3–1480 mL). Patients with TXA required 1–2 units less of transfusion and had 56–63 mL less of postoperative drainage versus no TXA. The median incidence of deep venous thrombosis (DVT) was 2.95% (0–7.9%) and for pulmonary embolism (PE) was 4.25% (0–14.3%). The use of TXA reduced intraoperative blood loss, transfusions and reduced postoperative surgical drainage output compared to no TXA use in patients with OSD. CONCLUSION: In this review, we found that TXA may diminish intraoperative blood loss, the need for transfusion and postoperative drainage from surgical drains when used in OSD without major increase in rates of DVT or PE. |
format | Online Article Text |
id | pubmed-9805626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Scientific Scholar |
record_format | MEDLINE/PubMed |
spelling | pubmed-98056262023-01-03 Antifibrinolytics use during surgery for oncological spine diseases: A systematic review Avila, Mauricio J. Orenday-Barraza, José Manuel Cavagnaro, María José Strouse, Isabel M. Farhadi, Dara S. Khan, Naushaba Hussein, Amna Baaj, Ali A. Surg Neurol Int Review Article BACKGROUND: Data exist of the benefits of antifibrinolytics such as tranexamic acid (TXA) in general spine surgery. However, there are limited data of its use in oncological spine patients. METHODS: A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Cochrane, OVID, and Embase databases were searched. Search terms: “tranexamic acid”, “aprotinin,” “aminocaproic acid,” “spine surgery,” “spine tumors,” and “spine oncology.” Included studies were full text publications written in English with patients treated with either agent or who had surgery for oncological spine disease (OSD). RESULTS: Seven hundred results were reviewed form the different databases, seven were selected. A total of 408 patients underwent spine surgery for OSD and received antifibrinolytics. There was a male predominance (55.2%) and mean age ranged from 43 to 62 years. The most common tumor operated was metastatic renal cancer, followed by breast and lung. Most studies administered TXA as a bolus followed by an infusion during surgery. Median blood loss was of 667 mL (253.3–1480 mL). Patients with TXA required 1–2 units less of transfusion and had 56–63 mL less of postoperative drainage versus no TXA. The median incidence of deep venous thrombosis (DVT) was 2.95% (0–7.9%) and for pulmonary embolism (PE) was 4.25% (0–14.3%). The use of TXA reduced intraoperative blood loss, transfusions and reduced postoperative surgical drainage output compared to no TXA use in patients with OSD. CONCLUSION: In this review, we found that TXA may diminish intraoperative blood loss, the need for transfusion and postoperative drainage from surgical drains when used in OSD without major increase in rates of DVT or PE. Scientific Scholar 2022-12-02 /pmc/articles/PMC9805626/ /pubmed/36600747 http://dx.doi.org/10.25259/SNI_837_2022 Text en Copyright: © 2022 Surgical Neurology International https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Avila, Mauricio J. Orenday-Barraza, José Manuel Cavagnaro, María José Strouse, Isabel M. Farhadi, Dara S. Khan, Naushaba Hussein, Amna Baaj, Ali A. Antifibrinolytics use during surgery for oncological spine diseases: A systematic review |
title | Antifibrinolytics use during surgery for oncological spine diseases: A systematic review |
title_full | Antifibrinolytics use during surgery for oncological spine diseases: A systematic review |
title_fullStr | Antifibrinolytics use during surgery for oncological spine diseases: A systematic review |
title_full_unstemmed | Antifibrinolytics use during surgery for oncological spine diseases: A systematic review |
title_short | Antifibrinolytics use during surgery for oncological spine diseases: A systematic review |
title_sort | antifibrinolytics use during surgery for oncological spine diseases: a systematic review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805626/ https://www.ncbi.nlm.nih.gov/pubmed/36600747 http://dx.doi.org/10.25259/SNI_837_2022 |
work_keys_str_mv | AT avilamauricioj antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT orendaybarrazajosemanuel antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT cavagnaromariajose antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT strouseisabelm antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT farhadidaras antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT khannaushaba antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT husseinamna antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview AT baajalia antifibrinolyticsuseduringsurgeryforoncologicalspinediseasesasystematicreview |